Year: 2022
Type: review
Abstract: Scientific advances over the last four decades have steadily infused the Alzheimer's disease (AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune activation states in the brain would provide disease modification. Unfortunately, this optimistic scenario has not yet played out. Though a recent approval of the anti-Aβ aggregate binding antibody, Aduhelm (aducanumab), as a "disease-modifying therapy for AD" is viewed by some as a breakthrough, many remain unconvinced by the data underlying this approval. Collectively, we have not succeeded in changing AD from a largely untreatable, inevitable, and incurable disease to a treatable, preventable, and curable one. Here, I will review the major foci of the AD "disease-modifying" therapeutic pipeline and some of the "open questions" that remain in terms of these therapeutic approaches. I will conclude the review by discussing how we, as a field, might adjust our approach, learning from our past failures to ensure future success.
Source: Neurotherapeutics
Author: Todd E. Golde
Institution: University of Florida
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Awards: 1Florida Alzheimer's Disease Research Center, APOE as a modifier of prion-like spread in dementia, Immunotherapy targeting the HPA axis in Alzheimer's disease, A Systems Approach to Targeting Innate Immunity in AD, Modulation of Alzheimers disease by Herpes simplex virus infection , Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
OpenAlex ID: W4214774022
